|Bid||177.65 x 1000|
|Ask||177.71 x 400|
|Day's Range||175.97 - 178.22|
|52 Week Range||145.12 - 191.10|
|PE Ratio (TTM)||16.08|
|Forward Dividend & Yield||4.60 (2.62%)|
|1y Target Est||N/A|
Biotech giant Amgen (AMGN) is providing some holiday cheer to investors with a 15% dividend increase. Last year Amgen paid out about one-third of its earnings in dividends. Shares of Amgen have gained 0.3% to $176.79 at 12:20 p.m. today, while the iShares Nasdaq Biotechnology ETF (IBB) has risen 0.3% to $106.09.
Amgen Inc said on Monday a final analysis of late-stage trial data showed that its Kyprolis combined with two other drugs helped blood cancer patients live longer. Kyprolis when used with two standard of care drugs, dexamethasone and Celgene Corp's Revlimid, reduced the risk of death by 21 percent and extended survival by 7.9 months, compared with patients treated with the two drugs alone, the company said. The study, ASPIRE, tested Kyprolis, chemically known as carfilzomib, in multiple myeloma patients whose cancer had relapsed following prior treatment or did not respond to treatment.
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Amgen, Inc. a score of 47. Our analysis is based on comparing Amgen, Inc. with the following peers – Pfizer Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc Sponsored ADR, Celgene Corporation, Gilead Sciences, Inc., AbbVie, Inc., Biogen Inc., Alexion Pharmaceuticals, Inc., Roche Holding Ltd Genusssch. and Johnson & ... Read more (Read more...)
Data presentations and regulatory updates were the key highlights this week with companies like AbbVie (ABBV) and Clovis providing data on their pipeline candidates.
23 analysts were tracking Pfizer in November 2017. One analyst recommended a “strong buy,” while 11 analysts recommended a “buy.”
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Amgen, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)
Amgen and Regeneron will battle in 2018 after the latter unveils cardiovascular data for its cholesterol drug Praluent.
Amgen (AMGN) announced FDA approval of its regulatory application seeking approval to expand Repatha's label to prevent heart attacks and strokes in patients with established cardiovascular disease.
Amgen Inc can now promote the ability of its potent but expensive cholesterol drug to reduce the risk of heart attacks and strokes, after U.S. health regulators approved adding those benefits to the medicine's prescribing label, the company said on Friday. Amgen has long seen this development as critical to clearing onerous hurdles to patient access and unlocking the value of the drug, Repatha, which has had anemic sales since its August 2015 approval despite its billion-dollar potential. The injected biotech drug was approved on the basis of its ability to dramatically lower bad LDL cholesterol.
23 analysts were tracking Bristol-Myers Squibb in November 2017. Six of them recommended a “strong buy” rating, while four recommended a “buy.”
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Amgen, Inc. Here are 5 ETFs with the largest exposure to AMGN-US. Comparing the performance and risk of Amgen, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
This could indicate that investors who seek to profit from falling equity prices are not currently targeting AMGN. Over the last one-month, outflows of investor capital in ETFs holding AMGN totaled $1.42 billion.
Ever wonder how your company retirement plan stacks up against the country's best employers? Take a peek at these great retirement plans.
Amgen could have an edge in the preventative migraine space where it competes against Teva, Lilly and Alder, an analyst says.